RT Journal Article
SR Electronic
T1 A global overview of genetically interpretable comorbidities among common diseases in UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.15.21249242
DO 10.1101/2021.01.15.21249242
A1 Guiying Dong
A1 Jianfeng Feng
A1 Fengzhu Sun
A1 Jingqi Chen
A1 Xing-Ming Zhao
YR 2021
UL http://medrxiv.org/content/early/2021/01/15/2021.01.15.21249242.abstract
AB Background Comorbidities greatly increase global health burdens, but the landscapes of their genetic factors have not been systematically investigated.Methods We used the hospital inpatient data of 385,335 patients in UK Biobank to investigate the comorbid relations among 439 common diseases. Post-GWAS analyses were performed to identify comorbidity shared genetic risks at the genomic loci, network, as well as overall genetic architecture levels. We conducted network decomposition for interpretable comorbidity networks to detect the hub diseases and the involved molecules in comorbidity modules.Results 11,285 comorbidities among 439 common diseases were identified, and 46% of them were genetically interpretable at the loci, network, or overall genetic architecture level. The comorbidities affecting the same and different physiological systems showed different patterns at the shared genetic components, with the former more likely to share loci-level genetic components while the latter more likely to share network-level genetic components. Moreover, both the loci- and network-level genetic components shared by comorbidities mainly converged on cell immunity, protein metabolism, and gene silencing. Furthermore, we found that the genetically interpretable comorbidities tend to form network modules, mediated by hub diseases and featuring physiological categories. Finally, we showcased how hub diseases mediating the comorbidity modules could help provide useful insights into the genetic contributors for comorbiditities.Conclusions Our results provide a systematic resource for understanding the genetic predispositions of comorbidity, and indicate that hub diseases and converged molecules and functions may be the key for treating comorbidity. We have created an online database to facilitate researchers and physicians to browse, search or download these comorbidities (https://comorbidity.comp-sysbio.org).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partly supported by National Key R&D Program of China (2020YFA0712403, 2018YFC0910500), National Natural Science Foundation of China (61932008, 61772368), and Shanghai Municipal Science and Technology Major Project (2018SHZDZX01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Access to the UK Biobank data was granted after registration. The application ID was 19542 for identifying multi-level biomarkers and mechanisms for diseases. The UK Biobank Study ethical approval had been granted by the National Information Governance Board for Health and Social Care and the NHS North West Multi-center Research Ethics Committee. Written informed consent was obtained from all participants. The pathway dataset was downloaded from MSigDB after registration. The Metathesaurus was obtained from UMLS after registration. Other datasets and tools (GWAS summary statistics, GRCh37.p13, CADD scores, dbscSNC scores, GTEx eQTL, MAGMA tool, MGI, ExAC database) used in this study are openly available to the public.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe epidemiological data used in the present study is available from UK Biobank with restrictions applied. Data were used under license and thus not publicly available. Access to the UK Biobank data can be requested through a standard protocol (https://www.ukbiobank.ac.uk/register-apply/). GWAS summary statistics used in this study can be accessed from http://geneatlas.roslin.ed.ac.uk. GRCh37.p13 is downloaded from https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.25/. The CADD scores are downloaded from https://cadd.gs.washington.edu. The dbscSNC scores are downloaded from ftp://dbnsfp:dbnsfp{at}dbnsfp.softgenetics.com. The GTEx eQTL data are downloaded from https://gtexportal.org/home/datasets. The MAGMA tool can be found at https://ctg.cncr.nl/software/magma. The Mouse Genome Informatics database is at http://www.informatics.jax.org. The MSigDB database is at https://www.gsea-msigdb.org/gsea/msigdb/index.jsp. The OMIM database is at https://omim.org/help/about. The UMLS description can be found at https://www.nlm.nih.gov/research/umls/index.html. The ExAC database is at https://gnomad.broadinstitute.org.